---
title: "eln_guideline_2024"
date: "2024-10-03"
tags:
  - building
---

> [!NOTE]
> ðŸŒ± created from: [[acute lymphoblastic leukemia]]

# eln_guideline_2024

![h:450px](https://i.imgur.com/V1MaWm5.png)

- Morphology of ALL
- Immunophenotyping of ALL
- Cytogenetics/Molecular genetics of ALL
- Establish MRD assay of ALL
- Clinical features of ALL
- Extended genomics, Biobanking

- Clinical: ALL, LL, CNS+or-
- Subsets and subtypesï¼š
  - Ph/BCRï¼šABL1+ï¼Œ
  - B/T-precursor Ph/BCR:ABL1-ï¼Œ
  - KMT2A rearrangements

![h:450px](https://i.imgur.com/3KaOEtF.png)

> 1.GÃ¶kbuget N, Boissel N, Chiaretti S, et al. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143(19):1891-1902. doi:10.1182/blood.2023020794

> 2.GÃ¶kbuget N, Boissel N, Chiaretti S, et al. Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143(19):1903-1930. doi:10.1182/blood.2023023568
